Neurotrophic support of midbrain dopaminergic neurons

Advances in Experimental Medicine and Biology

Volumn 651, Issue , 2009, Pages 73-80

  Von Bohlen Und Halbach, Oliver ^a   Unsicker, Klaus ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CILIARY NEUROTROPHIC FACTOR; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; NEUROTROPHIC FACTOR; NEUROTROPHIN; NEUROTROPHIN RECEPTOR; PLATELET DERIVED GROWTH FACTOR; SOMATOMEDIN; TRANSFORMING GROWTH FACTOR ALPHA; DOPAMINE; NERVE GROWTH FACTOR; SIGNAL PEPTIDE;

ARTICLE; CELL PROTECTION; CELL SURVIVAL; DOPAMINERGIC NERVE CELL; GENE MUTATION; HUMAN; KNOCKOUT MOUSE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN FUNCTION; ANIMAL; BRAIN TRANSPLANTATION; CYTOLOGY; GENETICS; GROWTH, DEVELOPMENT AND AGING; METABOLISM; METHODOLOGY; NERVE CELL; PHYSIOLOGY; REVIEW; SUBSTANTIA NIGRA;

ANIMALIA; MUS;

ANIMALS; BRAIN TISSUE TRANSPLANTATION; CELL SURVIVAL; CYTOPROTECTION; DOPAMINE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NERVE GROWTH FACTORS; NEURONS; PARKINSON DISEASE; SUBSTANTIA NIGRA;

EID: 70349787032     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-0322-8_7     Document Type: Article

References (76)

1. Chase TN, Oh JD, Blanchet PJ. Neostriatal mechanisms in Parkinson's disease. Neurology 1998; 51:S30-S35. (Pubitemid 28397141)
2. von Bohlen und Halbach O, Schober A, Krieglseeln K. Genes, proteins and neurotoxins involved in Parkinson's disease. Prog Neuro Biol 2004; 73: 151-177. (Pubitemid 38952827)
3. Krieglstein K. Factors promoting survival of mesencephalic dopaminergic neurons. Cell Tissue Res 2004; 318:73-80. (Pubitemid 39362628)
4. Unsicker K. Growth factors in Parkinson's disease. Prog Growth Factor Res 1994; 5:73-87.
5. Nagatsu T, Mogi M, Ichinose H et al. Cytokines in Parkinson's disease. J Neural Transm Suppl 2000; 143-151.
6. Reuss B, von Bohlen und Halbach O. Fibroblast growth factors and their receptors in the central nervous system. Cell Tissue Res 2003; 313:139-157. (Pubitemid 37129946)
7. Barde YA. Neurotrophins: a family of proteins supporting the survival of neurons. Prog Clin Biol Res 1994; 390:45-56.
8. Frade JM, Barde YA. Nerve growth factor: two receptors, multiple functions. Bioessays 1998; 20:137-145. (Pubitemid 28132109)
9. Barbacid M. The Trk family of neurotrophin receptors. J Neuro Biol1994; 25:1386-1403.
10. Chao MY. Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat Rev Neurosci 2003; 4:299-309.
11. Altar CA, Siuciak JA, Wright P et al In situ hybridization of trkB and trke receptor mRNA in rat forebrain and association with high-affinity binding of [125I]BDNF, [125I]NT-4/5 and [125I]NT-3. Eur J Neurosci 1994; 6:1389-1405. (Pubitemid 24280898)
12. Katoh-Semba R, Semba R, Takeuchi IK et al. Age-related changes in levels of brain-derived neurotrophic factor in selected brain regions of rats, normal mice and senescence-accelerated mice: a comparison to those of nerve growth factor and neurotrophin-3. Neurosci Res 1998; 31:227-234. (Pubitemid 28474939)
13. Nishio T, Furukawa S, Akiguchi I et al. Medial nigral dopamine neurons have rich neurotrophin support in humans. Neuro Report 1998; 9:2847-2851. (Pubitemid 28435175)
14. Numan S, Seroogy KB. Expression of trkB and trkC mRNAs by adult midbrain dopamine neurons: a double-label in situ hybridization study. J Comp Neurol 1999; 403:295-308. (Pubitemid 29006214)
15. Hyman C, Hofer M, Barde YA et al. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 1991; 350:230-232. (Pubitemid 21912205)
16. Hagg T. Neurotrophins prevent death and differentially affect tyrosine hydroxylase of adult rat nigrostriatal neurons in vivo. Exp Neurol 1998; 149:183-192. (Pubitemid 28091027)
17. Hynes MA, Poulsen K, Armanini Met al Neurotrophin-4/5 is a survival factor for embryonic midbrain dopaminergic neurons in enriched cultures. J Neurosci Res 1994; 37:144-154. (Pubitemid 24036485)
18. Hyman C, Juhasz M, Jackson C et al Overlapping and distinct actions of the neurotrophins BDNF, NT-3 and NT-4/5 on cultured dopaminergic and GABAergic neurons of the ventral mesencephalon. J Neurosci 1994; 14:335-347.
19. Baquet ZC, Bickford PC, Jones KR. Brain-derived neurotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia nigra pars compacta. J Neurosci 2005; 25:6251-6259. (Pubitemid 40923492)
20. Venero JL, Beck KD, Hefti F. 6-Hydroxydopamine lesions reduce BDNF mRNA levels in adult rat brain substantia nigra. NeuroReport 1994; 5:429-432. (Pubitemid 24128632)
21. Altar CA, Boylan CB, Fritsche M, et al Efficacy of brain- derivedneurotrophic factor and neurotrophin-3 on neurochemical and behavioral deficits associatedwith partial nigrostriatal dopamine lesions.J Neurochem 1994; 63:1021-1032. (Pubitemid 24266616)
22. Singh S, Ahmad R, Mathur D et al. Neuroprotective effect of BDNF in young and aged 6-OHDA treated rat model of Parkinson disease. Indian J Exp Biol 2006; 44:699-704. (Pubitemid 44369299)
23. Klein RL, Lewis MH, Muzyczka N et al. Prevention of 6-hydroxydopamine- induced rotational behavior by BDNF somatic gene transfer. Brain Res 1999; 847:314-320.
24. Levivier M, Przedborski S, Bencsics C, et al Intrastriatal implantation offibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease.J Neurosci 1995; 15:7810-7820. (Pubitemid 26006890)
25. Frim DM, Uhler TA, Galpern WR et al. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc Natl Acad Sci USA 1994; 91:5104-5108. (Pubitemid 24177801)
26. Galpern WR, Frim DM, Tatter SB et al. Cell-mediated delivery of brain-derived neurotrophic factor enhances dopamine levels in an MPP+ rat model of substantia nigra degeneration. Cell Transplant 1996; 5:225-232. (Pubitemid 26096182)
27. Howells DW Porritt MJ, Wong JY et al. Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra. Exp Neurol2000; 166:127-135.
28. Mogi M, Togari A, Kondo T et al. Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease. Neurosci Lett 1999; 270:45-48. (Pubitemid 29322994)
29. Zaman V, Nelson ME, Gerhardt GA et al. Neurodegenerative alterations in the nigrostriatal system of trkB hypomorphic mice. Exp Neurol2004; 190:337-346. (Pubitemid 39504991)
30. von Bohlen und Halbach O, Minichiello L, Unsicker K. Haploinsufficiency for trkB and trke receptors induces cell loss and accumulation of alpha-synuclein in the substantia nigra. FASEB J 2005; 19:1740-1742. (Pubitemid 41429548)
31. Kramer ER, Aron L, Ramakers GM et al. Absence of Ret Signaling in Mice Causes Progressive and Late Degeneration of the Nigrostriatal System. PLoS Biol 2007; 5:e39.
32. von Bohlen und Halbach O, Minichiello L. Neurotrophin receptor heterozygosity causes deficits in catecholaminergic innervation of amygdala and hippocampus in aged mice. J Neural Transm 2006; 113:1829-1836. (Pubitemid 44749622)
33. Dierssen M, Gratacos M, Sahun I et al Transgenic mice overexpressing the full-length neurotrophin receptor TrkC exhibit increased catecholaminergic neuron density in specific brain areas and increased anxiety-like behavior and panic reaction. Neuro Biol Dis 2006; 24:403-418. (Pubitemid 44592571)
34. Parain K, Murer MG, YanQet al. Reduced expression of brain-derived neurotrophic factor protein in Parkinson's disease substantia nigra. NeuroReport 1999; 10:557-561. (Pubitemid 29333282)
35. Porritt MJ, Batchelor PE, Howells DW: Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons. Exp Neurol2005; 192:226-234. (Pubitemid 40208556)
36. Momose Y Murata M, Kobayashi K, et al Association studies of multiple candidate genes for Parkinson's disease using single nucleotide polymorphisms. Ann Neurol 2002; 51:133-136. (Pubitemid 34027988)
37. Karamohamed S, Latourelle JC, Racette BA et al BDNF genetic variants are associated with onset age of familial Parkinson disease: GenePD Study. Neurology 2005; 65:1823-1825.
38. Parsian A, Sinha R, Racette B et al. Association of a variation in the promoter region of the brain-derived neurotrophic factor gene with familial Parkinson's disease. Parkinsonism Relat Disord 2004; 10:213-219. (Pubitemid 38534614)
39. Hong CJ, Liu HC, Liu TY et al. Brain-derived neurotrophic factor (BDNF) Val66Met polymorphisms in Parkinson's disease and age of onset. Neurosci Lett 2003; 353:75-77.
40. Saarela MS, Lehtimaki T, Rinne JO et al No association between the brain-derived neurotrophic factor 196 G > A or 270 C > T polymorphisms and Alzheimer's or Parkinson's disease. Folia Neuropathol 2006; 44: 12-16.
41. Xiromerisiou G, Hadjigeorgiou GM, Eerola J et al BDNF tagging polymorphisms and haplotype analysis in sporadic Parkinson's disease in diverse ethnic groups. Neurosci Lett 2007; 415:59-63. (Pubitemid 46380268)
42. Omitz DM, Itoh N. Fibroblast growth factors. Genome Biol 2001; 2:REVIEWS3005.
43. Powers CJ, McLeskey SW Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 2000; 7:165-197.
44. Unsicker K, Reuss B, von Bohlen und Halbach O. Fibroblast growth factors in brain functions. In: Lajtha A, Lim R, eds. Handbook of Neurochemistry and Molecular Neuro Biology. Neuroactive Proteins and Peptides, New York, Heidelberg: Springer; 2006:93-122.
45. Bean AJ, Elde R, Cao YH et al. Expression of acidic and basic fibroblast growth factors in the substantia nigra of rat, monkey and human. Proc Nad Acad Sci USA 1991; 88:10237-10241. (Pubitemid 21915810)
46. Cintra A, Cao YH, Oellig C et al. BasicFGF is present in doparninergic neurons of the ventral midbrain of the rat. NeuroReport 1991; 2:597-600.
47. Bean AJ. Oellig C, Pettersson RF et al. Differential expression of acidic and basic FGF in the rat substantia nigra during development. NeuroReport 1992; 3:993-996.
48. Ferrari G, Minozzi MC, Toffano G et al. Basic fibroblast growth factor promotes the survival and development of mesencephalic neurons in culture. Dev Biol 1989; 133:140-147. (Pubitemid 19118481)
49. Ferrari G, Minozzi MC, Toffano G et al Basic fibroblast growth factor affects the survival and development of mesencephalic neurons in culture. Adv Exp Med Biol 1990; 265:93-99. (Pubitemid 20189917)
50. Otto D, Unsicker K. Basic FGF reverseschemical and morphological deficits in the nigrostriatal system of MPTP-treated mice. J Neurosci 1990; 10:1912-1921.
51. Park TH, Mytilineou C. Protection from 1-methyl-4-phenylpyridinium (MPP+) toxicity and stimulation of regrowth of MPP{+)-damaged dopaminergic fibers by treatment of mesencephalic cultures with EGF and basic FGF. Brain Res 1992; 599:83-97. (Pubitemid 23024920)
52. Chadi G, Moller A, Rosen L et al. Protective actions of human recombinant basic fibroblast growth factor on MPTP-Iesioned nigrostriatal dopamine neurons after intraventricular infusion. Exp Brain Res 1993; 97:145-158. (Pubitemid 24045430)
53. Date I, Yoshimoto Y, Imaoka T et al. Enhanced recovery of the nigrostriatal dopaminergic system in MPTP-treated mice following intrastriatal injection of basic fibroblast growth factor in relation to aging. Brain Res 1993; 621: 150-154. (Pubitemid 23242175)
54. Otto D, Unsicker K. FGF-2-mediated protection of cultured mesencephalic dopaminergic neurons against MPTP and MPP+: specificity and impact of culture conditions, nondopaminergic neurons and astroglial cells. J Neurosci Res 1993; 34:382-393. (Pubitemid 23081783)
55. Casper D, Blum M. Epidermal growth factor and basic fibroblast growth factor protect dopaminergic neurons from glutamate toxicity in culture. J Neurochcm 1995; 65:1016-1026.
56. Shults CW Ray J, Tsuboi K et al. Fibroblast growth factor-2-producing fibroblasts protect the nigrostriatal dopaminergic system from 6-hydroxydopamine. Brain Res 2000; 883:192-204.
57. Leonard S, Luthman D, Logel J et al. Acidic and basic fibroblast growth factor mRNAs are increased in striatum following MPTP-induced dopamine neurofiber lesion: assay by quantitative PCR. Brain Res Mol Brain Res 1993; 18:275-284.
58. Rufer M, Wirth SB, Hofer A et al. Regulation of connexin-43, GFAP and FGF-2 is not accompanied by changes in astroglial coupling in MPTP-Iesioned, FGF-2-treated parkinsonian mice. J Neurosci Res 1996; 46:606-617. (Pubitemid 26404653)
59. Giacobini MM, Stromberg I, Almstrom S et al. Fibroblast growth factors enhance dopamine fiber formation from nigral grafis, Brain Res Dev Brain Res 1993; 75:65-73. (Pubitemid 23265089)
60. Mayer E, Fawcett JW Dunnett SB. Basic fibroblast growth factor promotes the survival of embryonic ventral mesencephalic dopaminergic neurons-II. Effects on nigral transplants in vivo. Neuroscience 1993; 56:389-398. (Pubitemid 23274758)
61. Takayama H, Ray J, Raymon HK et al. Basic fibroblast growth factor increases dopaminergic grafi survival and function in a rat model of Parkinson's disease. Nat Med 1995; 1:53-58.
62. Timmer M, Muller-Ostermeyer F, Kloth V, et al. Enhanced survival, reinnervation and functional recovery of intrastriatal dopamine grafis cotransplanted with Schwann cells overexpressing high molecular weight FGF-2 isoforms. Exp Neurol2004; 187:118-136. (Pubitemid 38470018)
63. Zechel S, Jarosik J, Kiprianova I, et al. FGF-2 deficiency does not alter vulnerability of the dopaminergic nigrostriatal system towards MPTP intoxication in mice. Eur J Neurosci 2006; 23:1671-1675.
64. Timmer M, Cesnulevicius K, Winkler C et al. Fibroblast growth factor (FGF)-2 and FGF receptor 3 are required for the development of the substantia nigra and FGF-2 plays a crucial role for the rescue of dopaminergic neurons atter 6-hydroxydopamine lesion. J Neurosci 2007; 27:459-471. (Pubitemid 46143751)
65. von Bohlen und Halbach, O. Modeling neurodegenerative diseases in vivo review. Neurodegenerative Dis. 2006; 2:313-320.
66. Ohmachi S, Watanabe Y, Mikami T et al. FGF-20, a novel neurotrophic factor, preferentially expressed in the substantia nigra pars compacta of rat brain. Biochem Biophys Res Commun 2000; 277:355-360.
67. Grothe C, Timmer M, Scholz T et al. Fibroblast growth factor-20 promotes the differentiation of Nurr1-overexpressing neural stem cells into tyrosine hydroxylase-positive neurons. Neuro Biol Dis 2004; 17:163-170. (Pubitemid 39345772)
68. Murase S, McKay RD. A specific survival response in dopamine neurons at most risk in Parkinson's disease. J Neurosci 2006; 26:9750-9760. (Pubitemid 44427714)
69. van der Walt JM, Noureddine MA, Kittappa R et al. Fibroblast growth factor 20 polymorphisms and haplorypes strongly influence risk of Parkinson disease. Am J Hum Genet 2004; 74: 1121-1127. (Pubitemid 38669311)
70. Satake W, Mizuta I, Suzuki S et al. Fibroblast growth factor 20 gene and Parkinson's disease in the Japanese population. NeuroReport 2007; 18:937-940. (Pubitemid 46791528)
71. Clarimon J, Xiromerisiou G, Eerola J et al. Lack of evidence for a genetic association between FGF20 and Parkinson's disease in Finnish and Greek patients. BMC Neurol2005; 5:11.
72. Blum M. A null mutation in TGF-alpha leads to a reduction in midbrain dopaminergic neurons in the substantia nigra. Nat Neurosci 1998; 1:374-377.
73. Nikkhah G, Odin P, Smits A et al. Platelet-derived growth factor promotes survival of rat and human mesencephalic dopaminergic neurons in culture. Exp Brain Res 1993; 92:516-523.
74. Mohapel P, Frielingsdorf H, Haggblad J et al. Platelet-derived growth factor (PDGF-BB) and brain-derived neurotrophic factor (BDNF) induce striatal neurogenesis in adult rats with 6-hydroxydopamine lesions. Neuroscience 2005; 132:767-776.
75. Hagg T, Varon S. Ciliary neurotrophic factor prevents degeneration of adult rat substantia nigra dopaminergic neurons in vivo. Proc Natl Acad Sci USA 1993; 90:6315-6319. (Pubitemid 23191506)
76. Akaneya Y, Takahashi M, Hatanaka H. Interleukin-1 beta enhances survival and interleukin-6 protects against MPP+ neurotoxicity in cultures of fetal rat dopaminergic neurons. Exp Neurol 1995; 136:44-52.